SCHEMBL3633436

SCHEMBL3633436

Cc1cc(C)nc(C(=O)O)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPK1 P28482 1/20 0.50
KDM4E B2RXH2 4/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.43
HCAR2 Q8TDS4 1/20 0.43
POLB P06746 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TPMT P51580 1/20 0.40
LCK P06239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28322157 0.84 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT
SCHEMBL7013053 0.80 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT
SCHEMBL13531338 0.80 HTT (0.48) SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT
SCHEMBL874706 0.78 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT
SCHEMBL28344661 0.76 VCP (0.52) SMN1; SMN2ALDH1A1KDM4EMAPTLMNA
SCHEMBL1179149 0.76 TPMT (0.56) SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT
SCHEMBL2469053 0.76 HTT (0.56) ALDH1A1MAPK1KDM4EMAPTLMNA
SCHEMBL1146219 0.75 TSHR (0.38) SMN1; SMN2ALDH1A1MAPK1KDM4EMAPT
SCHEMBL1799136 0.74 KMO (0.46) SMN1; SMN2ALDH1A1MAPK1KMT2AMEN1
SCHEMBL10110991 0.74 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1MAPK1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025068514-A1 SUBSTITUTED HETEROCYCLIC CARBOXAMINDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2025-04-03 WO disclosed
CN-118436562-A Composition for improving mitochondrial autophagy function and application thereof 山东福瑞达生物股份有限公司 2024-08-06 CN disclosed
CN-116327636-B Moisturizing repair composition, application and preparation method thereof 山东福瑞达生物股份有限公司 2024-06-25 CN disclosed
CN-116327636-A Moisturizing repair composition, application and preparation method thereof 山东福瑞达生物股份有限公司 2023-06-27 CN disclosed
EP-2530078-A1 THIAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2012-12-05 EP disclosed
EP-2142555-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-Roche AG (CH) 2010-01-13 EP disclosed
US-7625891-B2 Heterocylic antiviral compounds ROCHE PALO ALTO LLC (US) 2009-12-01 US disclosed
US-20090093501-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2009-04-09 US disclosed
WO-2009037168-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2009-03-26 WO disclosed
WO-2008119663-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 WO disclosed
US-20080249087-A1 Heterocylic antiviral compounds ROCHE PALO ALTO LLC 2008-10-09 US disclosed
EP-0353640-B2 Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators BAYER CROPSCIENCE GMBH (DE) 2003-10-15 EP disclosed
EP-0353640-B1 Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators HOECHST SCHERING AGREVO GMBH (DE) 1995-04-12 EP disclosed
US-5186736-A Pre- and postemergence HOECHST AKTIENGESELLSCHAFT (DE) 1993-02-16 US disclosed
US-5053072-A HETEROCYCLIC N-ACYLSULFONAMIDES, AND THEIR USE AS HERBICIDES OR GROWTH REGULATORS HOECHST AKTIENGESELLSCHAFT (DE) 1991-10-01 US disclosed
EP-0353640-A2 Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators Hoechst Schering AgrEvo GmbH (DE) 1990-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093501-A1 Heterocyclic antiviral compounds CCR5, CCR1, CCR2 SMN1; SMN2 3148/4885ALDH1A1 662/4885MAPK1 2288/4885
US-20080249087-A1 Heterocylic antiviral compounds CCR5, CCR1, CXCR1 SMN1; SMN2 3620/4885ALDH1A1 339/4885MAPK1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.